INT117075

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 2004
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 14
Disease Relevance 9.51
Pain Relevance 3.91

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Ikbkb) kinase activity (Ikbkb) cytoplasm (Ikbkb)
Ikbkb (Rattus norvegicus)
Pain Link Frequency Relevance Heat
aspirin 4 99.18 Very High Very High Very High
cytokine 132 98.64 Very High Very High Very High
Inflammation 256 98.60 Very High Very High Very High
Potency 24 98.32 Very High Very High Very High
Neuropathic pain 1 97.92 Very High Very High Very High
Clonidine 3 97.40 Very High Very High Very High
Arthritis 120 97.00 Very High Very High Very High
Bioavailability 48 96.40 Very High Very High Very High
rheumatoid arthritis 60 94.96 High High
Inflammatory mediators 12 94.48 High High
Disease Link Frequency Relevance Heat
Insulin Resistance 8 99.92 Very High Very High Very High
INFLAMMATION 243 98.60 Very High Very High Very High
Neuropathic Pain 1 97.92 Very High Very High Very High
Hypersensitivity 72 97.40 Very High Very High Very High
Arthritis 121 97.00 Very High Very High Very High
Autoimmune Disease 144 96.48 Very High Very High Very High
Pressure And Volume Under Development 60 95.80 Very High Very High Very High
Pneumonia 12 95.52 Very High Very High Very High
Disease 60 95.16 Very High Very High Very High
Rheumatoid Arthritis 60 94.96 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
IKK2 inhibitors
Negative_regulation (inhibitors) of IKK2
1) Confidence 0.26 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.36 Pain Relevance 0.18
Structural modification of SC-415, a known weak but selective IKK2 inhibitor [15], has yielded compound 8 and analogs with modest IKK2 inhibitory potency [16].
Negative_regulation (inhibitor) of IKK2 associated with potency
2) Confidence 0.26 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.79 Pain Relevance 0.41
This review will cover the recent publications, primarily from 2006–2007, describing inhibitors of IKK2 (I?
Negative_regulation (inhibitors) of IKK2
3) Confidence 0.26 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.61 Pain Relevance 0.11
A series of 2-anilino-4-arylpyrimidines such as compound 5 have been reported to be potent IKK2 inhibitors with IC50?
Negative_regulation (inhibitors) of IKK2
4) Confidence 0.23 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.22 Pain Relevance 0
This review describes some of the recent developments in the search for inhibitors of IKK2, Syk, Lck, and JAK3 kinases.
Negative_regulation (inhibitors) of IKK2
5) Confidence 0.19 Published 2008 Journal Purinergic Signal Section Abstract Doc Link PMC2721774 Disease Relevance 0.34 Pain Relevance 0.08
An anilinopyrimidine derivative, 10, has been reported to be a potent IKK2 inhibitor with IC50?
Negative_regulation (inhibitor) of IKK2
6) Confidence 0.19 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.59 Pain Relevance 0.26
A structurally related compound TPCA-1 has been reported to be an ATP-competitive and selective inhibitor of IKK2 with IC50?
Negative_regulation (inhibitor) of IKK2
7) Confidence 0.19 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.91 Pain Relevance 0.45
333 nM for inhibition of IKK2, inhibited IL-8 production in IL-1?
Negative_regulation (inhibition) of IKK2
8) Confidence 0.19 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.93 Pain Relevance 0.46
Inhibition of IKK2 has been pursued as a potential therapy to treat disorders related to inflammation and autoimmunity.
Negative_regulation (Inhibition) of IKK2 associated with autoimmune disease and inflammation
9) Confidence 0.19 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.90 Pain Relevance 0.23
Compound 7 has been reported to be a potent, ATP-competitive, and moderately selective inhibitor of IKK2 with Ki?
Negative_regulation (inhibitor) of IKK2
10) Confidence 0.19 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.64 Pain Relevance 0.34
PS-1145 has been reported to be a potent IKK2 inhibitor with IC50?
Negative_regulation (inhibitor) of IKK2
11) Confidence 0.19 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.46 Pain Relevance 0.19
Compound 9, an isomer of TPCA-1, has been reported to be a potent inhibitor of IKK2 with IC50?
Negative_regulation (inhibitor) of IKK2
12) Confidence 0.19 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.80 Pain Relevance 0.37
In behavioral experiments, inhibition of nuclear factor-kappaB activation by systemic administration of the IkappaB kinase inhibitor S1627 has been shown to attenuate inflammatory and neuropathic pain.
Negative_regulation (inhibitor) of IkappaB kinase associated with inflammation and neuropathic pain
13) Confidence 0.09 Published 2006 Journal Neuroreport Section Abstract Doc Link 17001279 Disease Relevance 0.41 Pain Relevance 0.41
Only clonidine treatment totally prevented the development of insulin resistance, and high-dose aspirin, known to prevent insulin resistance by inhibition of the activity of IkappaB kinase-beta, decreased the degree of insulin resistance by almost 70%.
Negative_regulation (inhibition) of IkappaB kinase-beta associated with aspirin, insulin resistance and clonidine
14) Confidence 0.00 Published 2004 Journal Hypertension Section Abstract Doc Link 15007033 Disease Relevance 1.56 Pain Relevance 0.40

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox